info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
16
Mar
CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update
9
Mar
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
1
Mar
CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
6
Feb
CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference
30
Jan
CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
24
Jan
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
23
Jan
CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
8
Jan
CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis
14
Nov
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update
7
Nov
CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022
4
Nov
CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022
3
Nov
CymaBay Therapeutics to Present at Upcoming Investment Conferences
1
Nov
CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development
3
Oct
CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022
14
Sep
CymaBay Therapeutics Hosting Virtual Analyst Day on September 22
6
Sep
CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
24
Aug
CymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022
11
Aug
CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update
4
Aug
CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022
1
Aug
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis
22
Jun
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022
8
Jun
CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2022
23
May
CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
12
May
CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update
11
May
CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022
5
May
CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022
4
Apr
CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis
17
Mar
CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors
17
Mar
CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update
10
Mar
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022
10
Feb
CymaBay Therapeutics to Present at Upcoming Investor Conferences
18
Nov
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
17
Nov
CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
15
Nov
CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biomarkers in Patients with PBC
11
Nov
CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis
10
Nov
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update
4
Nov
CymaBay Therapeutics to Present at Upcoming Investor Conferences
3
Nov
CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
1
Oct
CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2021
30
Aug
CymaBay Therapeutics to Present at Upcoming Investor Conferences
12
Aug
CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
5
Aug
CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
2
Aug
CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth
21
Jun
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021
14
Jun
CymaBay Therapeutics to Present at Upcoming Investor Conferences
9
Jun
CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2021
18
May
CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
13
May
CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update
13
May
CymaBay Welcomes Dennis D. Kim, MD, MBA as Chief Medical Officer
11
May
CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10
May
CymaBay Names Lewis Stuart Chief Commercial Officer
6
May
CymaBay Therapeutics to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
5
Apr
CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors
25
Mar
CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
12
Mar
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021
11
Mar
CymaBay Therapeutics to Present at the 2021 NASH-TAG Conference
24
Feb
CymaBay Therapeutics to Present at Upcoming Investor Conferences
10
Feb
CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference
16
Nov
CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020
11
Nov
CymaBay Therapeutics to Present at Upcoming Investor Conferences
5
Nov
CymaBay Reports Third Quarter 2020 Financial Results and Provides Corporate Update
5
Nov
CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes
2
Nov
CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020
30
Oct
CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
1
Oct
CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting® 2020
3
Sep
CymaBay Therapeutics to Present at Upcoming Investor Conferences
27
Aug
CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress™ 2020
20
Aug
CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020
10
Aug
CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update
3
Aug
CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
3
Aug
CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis
23
Jul
FDA Lifts All Clinical Holds on Seladelpar
19
Jun
CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education
5
Jun
Notice of Change of Location of Annual Meeting of Stockholders to be Held on June 23, 2020
11
May
CymaBay Reports First Quarter 2020 Financial Results and Provides Corporate Update
4
May
CymaBay Therapeutics to Report First Quarter 2020 Financial Results on Monday, May 11
13
Mar
CymaBay Therapeutics Comments on Engine Capital Director Nominations
12
Mar
CymaBay Reports Fourth Quarter and Fiscal Year End 2019 Financial Results and Provides Corporate Update
5
Mar
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 12
29
Jan
CymaBay Publishes Shareholder Letter
25
Nov
CymaBay Therapeutics Halts Clinical Development of Seladelpar
14
Nov
CymaBay Therapeutics to Present at Upcoming Investor Conferences
5
Nov
CymaBay Reports Third Quarter 2019 Financial Results and Provides Corporate Update
4
Nov
CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis
28
Oct
CymaBay Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 5
14
Oct
CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference
1
Oct
CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2019
30
Sep
CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
17
Sep
CymaBay Therapeutics Announces Departure of Chief Medical Officer
3
Sep
CymaBay Therapeutics to Present at Upcoming Investor Conferences in September
7
Aug
CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update
5
Aug
CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer
31
Jul
CymaBay Therapeutics to Report Second Quarter 2019 Financial Results on Wednesday, August 7
18
Jun
CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis
17
Jun
CymaBay Therapeutics to Participate in the Raymond James Life Sciences and MedTech Conference
11
Jun
CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
20
May
CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019
8
May
CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update
8
May
CymaBay Therapeutics Announces Multiple Presentations at DDW 2019
30
Apr
CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8
12
Apr
CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress™ 2019
27
Mar
CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference™ 2019
12
Mar
CymaBay Therapeutics to Present at Upcoming Investor Conferences in March
11
Mar
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
6
Mar
CymaBay Announces Pricing of Public Offering of Common Stock
5
Mar
CymaBay Announces Proposed Public Offering of Common Stock
28
Feb
CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update
21
Feb
CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28
20
Feb
CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
19
Feb
CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
15
Feb
CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis
2
Jan
CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
20
Nov
CymaBay Therapeutics to Participate in Upcoming Investor Conferences
13
Nov
CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018
6
Nov
CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update
30
Oct
CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6
30
Oct
CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates
3
Oct
CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver Meeting®
24
Sep
CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October
14
Aug
CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September
9
Aug
CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update
2
Aug
CymaBay to Report Second Quarter 2018 Financial Results on Thursday, August 9
25
Jun
CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes
19
Jun
CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018
8
May
CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update
8
May
CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis
1
May
CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8
11
Apr
CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2018
15
Mar
CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update
6
Mar
CymaBay to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15
5
Mar
CymaBay Therapeutics to Participate in Upcoming Investor Conferences in March
6
Feb
CymaBay Therapeutics to Participate in Investor Conferences in February
1
Feb
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
30
Jan
CymaBay Announces Pricing of Public Offering of Common Stock
29
Jan
CymaBay Announces Proposed Public Offering of Common Stock
8
Jan
Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis
8
Jan
CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America
2
Jan
CymaBay Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
4
Dec
CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel
13
Nov
CymaBay Therapeutics to Present at Three Investor Conferences
8
Nov
CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates
1
Nov
CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8
31
Oct
CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer
23
Oct
CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis
9
Oct
CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting
18
Sep
CymaBay Therapeutics to Present at Two Investor Conferences
11
Sep
CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis
15
Aug
CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology
10
Aug
CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update
7
Aug
CymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10
24
Jul
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
19
Jul
CymaBay Announces Pricing of Public Offering of Common Stock
17
Jul
CymaBay Announces Proposed Public Offering of Common Stock
17
Jul
CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis
26
Jun
CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance
11
May
CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update
4
May
CymaBay to Report First Quarter 2017 Financial Results on Thursday, May 11
13
Apr
CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017
30
Mar
CymaBay Therapeutics to Present at Two Investor Conferences in April
29
Mar
CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D.
23
Mar
CymaBay Reports Fourth Quarter and Year End 2016 Financial Results
16
Mar
CymaBay to Report Fourth Quarter And Year End 2016 Financial Results on Thursday, March 23
9
Mar
CymaBay Therapeutics to Present at Two Investor Conferences in March
7
Feb
CymaBay Therapeutics to Present at the 2017 BIO CEO & Investor Conference
2
Feb
CymaBay Announces Pricing of Public Offering of Common Stock
1
Feb
CymaBay Announces Proposed Public Offering of Common Stock
5
Jan
CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate
3
Jan
CymaBay Announces Exclusive Licensing Agreement with Kowa Pharmaceuticals America, Inc. for the Development and Commercialization of Arhalofenate in the United States
8
Dec
CymaBay Announces the Appointments of Robert Booth, Ph.D. and Caroline Loewy to Its Board of Directors
7
Dec
CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis
6
Dec
CymaBay Therapeutics Announces that the Recommended International Nonproprietary Name for MBX-8025 is Seladelpar
28
Nov
CymaBay Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference
10
Nov
CymaBay to Host Key Opinion Leader Meeting on Primary Biliary Cholangitis in New York City
10
Nov
CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 for the Treatment of Primary Biliary Cholangitis
9
Nov
CymaBay Reports Third Quarter 2016 Financial Results
9
Nov
CymaBay Therapeutics Announces a Newly Issued U.S. Patent for the Use of MBX-8025 as a Treatment for Primary Biliary Cholangitis (PBC)
2
Nov
CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9
20
Oct
CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting
20
Oct
CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines (PRIME) Designation for the Treatment of Primary Biliary Cholangitis
11
Oct
CymaBay Therapeutics Announces a Newly Issued U.S. Patent for MBX-8025 for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
6
Oct
CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclinical Model of NASH at the AASLD 2016 Liver Meeting
5
Oct
CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis
8
Sep
CymaBay Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
9
Aug
CymaBay Reports Second Quarter 2016 Financial Results
2
Aug
CymaBay to Announce Second Quarter 2016 Financial Results on Tuesday, August 9
7
Jul
CymaBay Announces Participation at Cantor Fitzgerald Healthcare Conference on July 12th in New York
31
May
CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
19
May
CymaBay Therapeutics to Present at UBS Global Healthcare Conference
11
May
CymaBay Reports First Quarter 2016 Financial Results
2
May
CymaBay to Announce First Quarter 2016 Financial Results on Wednesday, May 11
29
Mar
CymaBay Reports Fourth Quarter and Full Year 2015 Financial Results
28
Mar
CymaBay Announces the Appointment of Paul F. Truex and Robert J. Weiland to its Board of Directors
28
Mar
CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology
22
Mar
CymaBay Announces the Appointment of Dr. Evan Stein, M.D., Ph.D., to its Board of Directors
21
Mar
CymaBay to Announce Fourth Quarter and Year-End 2015 Financial Results on Tuesday, March 29
17
Mar
CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia
3
Mar
CymaBay Therapeutics to Present at Two Upcoming Investor Conferences in March
2
Feb
CymaBay Therapeutics to Present at the BIO CEO & Investor Conference
20
Jan
CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate
6
Jan
CymaBay Therapeutics to Present at the Biotech Showcase 2016
13
Nov
CymaBay Announces Participation at Three Upcoming Investor Conferences
12
Nov
CymaBay Announces Third Quarter Financial Results
10
Nov
CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis
5
Nov
CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology (ACR) Annual Meeting, November 6 - 11
4
Nov
CymaBay to Announce Third Quarter 2015 Financial Results on Thursday, November 12
8
Oct
CymaBay Announces the Appointment of Robert J. Wills, Ph.D., as Chairman of the Board of Directors
3
Sep
CymaBay Therapeutics to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
10
Aug
CymaBay Announces Second Quarter 2015 Financial Results
6
Aug
CymaBay Strengthens the Intellectual Property of Arhalofenate With Issuance of Two New Patents
3
Aug
CymaBay to Announce Second Quarter 2015 Financial Results on Monday, August 10
27
Jul
CymaBay Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
15
Jul
CymaBay Therapeutics Announces Pricing of $20 Million Public Offering of Common Stock
14
Jul
CymaBay Announces Proposed Public Offering of Common Stock
6
Jul
CymaBay Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
12
Jun
CymaBay Therapeutics Presents Poster at EULAR 2015
29
May
CymaBay to Present at the Jefferies 2015 Global Healthcare Conference
15
May
CymaBay to Present at the 2015 UBS Global Healthcare Conference
7
May
CymaBay Reports First Quarter 2015 Financial Results
1
May
CymaBay to Announce First Quarter 2015 Financial Results on Thursday, May 7, 2015
23
Apr
CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia
22
Apr
CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
20
Apr
CymaBay Therapeutics Strengthens Management Team With the Appointment of Kirk Rosemark to VP, Regulatory Affairs and Quality Assurance
7
Apr
CymaBay to Present at the 14th Annual Needham Healthcare Conference
25
Mar
CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia
24
Mar
CymaBay Therapeutics Appoints Robert J. Wills, Ph.D. to Board of Directors
23
Mar
CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City
18
Mar
CymaBay Reports Fourth Quarter and Full Year 2014 Financial Results
11
Mar
CymaBay Therapeutics to Announce Fourth Quarter and Year-End 2014 Financial Results and Business Update on Wednesday, March 18, 2015
27
Feb
CymaBay to Present at Upcoming Investor Conferences
24
Feb
CymaBay Therapeutics Announces Positive Results From Its Phase 2b Clinical Study Demonstrating That Arhalofenate Met the Primary Endpoint of Reduction in Gout Flares
4
Feb
CymaBay to Present at 17th Annual BIO CEO & Investor Conference
28
Jan
CymaBay Therapeutics Announces Preclinical Data Demonstrating the Potential of MBX-8025 to Treat Homozygous Familial Hypercholesterolemia
12
Jan
Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat
26
Nov
CymaBay Therapeutics to Present at the Piper Jaffray 26th Annual Healthcare Conference
12
Nov
CymaBay Reports Third Quarter 2014 Financial Results
31
Oct
CymaBay Therapeutics to Announce Third Quarter 2014 Financial Results on Wednesday, November 12, 2014
15
Oct
CymaBay Therapeutics to Participate in Two Upcoming Investor Conferences
29
Sep
CymaBay Completes Enrollment in its Phase 2b Study of Arhalofenate in Patients with Gout
28
Jul
CymaBay Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
22
Jul
CymaBay Therapeutics Announces Pricing of Public Offering of Common Stock
17
Jul
CymaBay Therapeutics Announces Proposed Offering of Common Stock
16
Jun
CymaBay Therapeutics Announces Uplisting to the NASDAQ Capital Market Under the Symbol "CBAY"
2
Jun
CymaBay Therapeutics to Present at Upcoming Conferences
26
Mar
CymaBay Initiates Arhalofenate Phase 2b Gout Study
3
Mar
CymaBay Therapeutics Appoints Pol Boudes M.D. to Position of Chief Medical Officer
25
Feb
CymaBay Therapeutics to Present at Cowen and Roth Investor Conferences
3
Feb
CymaBay to Present at 16th Annual Bio CEO & Investor Conference
24
Jan
CymaBay Therapeutics Announces Listing on OTCBB and OTC Link
13
Jan
Sujal Shah Appointed Chief Financial Officer of CymaBay Therapeutics
11
Dec
CymaBay Therapeutics, Inc. Completes Financing
10
Dec
Metabolex Undergoes Capital Restructure and Renames as CymaBay Therapeutics
8
Dec
Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
29
Nov
Metabolex Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch
1
Nov
Metabolex to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011 ACR/ARHP Annual Scientific Meeting
19
May
Metabolex Initiates Phase 2 Trial of Arhalofenate
22
Jun
Metabolex Enters Into Type 2 Diabetes Development and License Agreement
Scroll
